anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a transdermal therapeutic system (TTS) for transcutaneal administration of sexual steroid hormones over long periods. The inventive system consists of a fixing aid and a polymethacrylate-based matrix containing steroid hormones. The invention also relates to a solvent-free, active substance-saving method for the production thereof. The inventive TTS  is characterized by physical and chemical stability. It displays good adhesive properties over long periods of administration and releases high rates of active substance per surface unit through the skin. One advantage of the production process is that the active substances are subjected to as little thermal exposure as possible, thereby minimizing decomposition or disintegration reactions of said active substances.
PURPOSE: A pharmaceutical composition containing poly amino acid and anionic polysaccharide for administering lipase inhibitor is provided to maintain pharmacological effect of the inhibitor and reduce involuntary release of oil from anus. CONSTITUTION: A pharmaceutical composition for administering lipase inhibitor contains anionic polysaccharide and poly amino acid. The composition additionally contains lipase inhibitor, orlistat. The anionic polysaccharide is pectin, alginic acid, propyleneglycol, carrageeenan, carboxyalkyl cellulose and its salt, Arabic gum, xanthangum, hyaluronic acid or chondroitin sulfate. The poly amino acid is poly lysine, poly arginine, poly serine, poly glycine, poly aspartic acid, poly aspartic acid, poly glutamic acid, polyalanine or polyornithine. The composition further contains guar gum or locust bean gum. A method for producing the pharmaceutical composition comprises: a step of dissolving or dispersing anionic polysaccharide in water or organic solvent; and a step of gelling the poly amino acid.
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite advances in treatment, mechanisms underlying GBM invasion remain incompletely understood. This systematic review synthesizes findings from laboratory and clinical studies to elucidate the molecular mechanisms driving GBM invasion and their implications for prognosis and therapy. This review adhered to PRISMA guidelines, conducting a comprehensive search of PubMed/Medline for studies published up to October 16, 2023. Inclusion criteria focused on studies investigating molecular mechanisms of GBM invasiveness with reported clinical outcomes (overall survival (OS) and progression-free survival (PFS). Exclusion criteria included systematic reviews, case reports, small case series, and studies limited to preclinical data. Risk of bias was assessed using the ROBINS-I tool. From 831 records, 21 studies (2198 patients) met the criteria. Key GBM invasion mechanisms included ECM degradation, vascular invasion, EMT, apoptotic regulation, cytoskeletal organization, and RNA sequencing. Vascular mechanisms were most studied. Bevacizumab resistance linked to poorer outcomes. EMT markers like TWIST and ECM degradation via MMPs such as CD147 correlated with decreased survival. Cytoskeletal and RNA studies highlighted the prognostic significance of tumor subtypes and microenvironmental interactions. This systematic review elucidates the molecular mechanisms underlying GBM invasiveness and their clinical implications. Integrating molecular profiling into routine clinical assessment may enhance prognostic accuracy and therapeutic efficacy, paving the way for personalized treatment strategies.
B vitamins in the human distal gut are primarily derived from the gut microbiota because daily dietary vitamins are fully absorbed in the small intestine under normal dietary and physiological conditions. Quantitative determination of B vitamins in the distal gut and faecal samples is crucial for understanding the intricate relationship between gut B vitamins, gut microbiota, and host health. In this study, we developed a rapid, robust, and reliable method with a simple extraction procedure for the simultaneous analysis of seven B vitamins in human faeces using high-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry (HPLC-ESI-MS/MS) with stable isotope-labelled internal standards. A protein precipitation approach using methanol as the precipitant was employed to extract vitamin B from human faecal samples. Seven B vitamins were adequately separated and quantified within 9 min by HPLC-ESI-MS/MS with a Pursuit PFP column (2.0 ×150 mm, 3.0 µm), including vitamins B1, B2, B3, B5, pyridoxic acid, pyridoxine, and B7. The lower limits of quantification were within the range of 0.1-25 ng mL-1. The intra-day and inter-day precision and accuracy were both within 15 %. The validated method was successfully applied to 55 faecal samples collected from healthy individuals, patients with type 2 diabetes, and obese patients. Compared with healthy controls, obese patients had lower faecal concentrations of vitamins B1 and B3 and pyridoxic acid, whereas patients with type 2 diabetes had lower faecal concentrations of vitamins B1 and B5.
DO NOT INJECT INTRAVENOUSLY.

Epinephrine 1:1000 should be available.

Concentrated extracts must be diluted with sterile diluent prior to first use on a patient for treatment or intradermal testing. All concentrates of glycerinated allergenic extracts have the ability to cause serious local and systemic reactions including death in sensitive patients. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and /or death.(4)(See Adverse Reactions) An allergenic extract should be temporarily withheld from patients or the dose of the extract adjusted downward if any of the following conditions exist: (1) Severe symptoms of rhinitis and/or asthma (2) Infections or flu accompanied by fever and (3) Exposure to excessive amounts of clinically relevant allergen prior to a scheduled injection. When switching patients to a new lot of the same extract the initial dose should be reduced 3/4 so that 25% of previous dose is administered.
Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with MYALEPT. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of MYALEPT efficacy. Severe infection and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of MYALEPT efficacy during treatment. Contact Chiesi Farmaceutici S.p.A. at 1-866-216-1526 for neutralizing antibody testing of clinical samples [see Contraindications (4.1) and Warnings and Precautions (5.1)].

T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with MYALEPT. Carefully consider the benefits and risks of treatment with MYALEPT in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy [see Warnings and Precautions (5.2)].

Because of these risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and/or MYALEPT and the risk for lymphoma, MYALEPT is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYALEPT REMS PROGRAM [see Warnings and Precautions (5.3)].
FIELD: food, perfume-cosmetic and medicinal industries. SUBSTANCE: biologically active food additive in the form of macro- and microelements, adaptogen and/or detoxicant contains algae with reduced content of toxic elements. Algae are prepared by extraction with organic solvent with a number of carbon atoms from one to six at ratio of raw material : solvent being equal to 1: (1-20). Content of alginic acid is not more 55 mas.%, iodine, up to 0.25 mas.%. The biologically active additive may additionally include vitamins, and/or provitamins, and/or tannins, and/or saponins, and/or glycosides, and/or sterols, and/or polysaccarides, and/or food tissues, and/or cellulose. As their source, the biologically active additive contains vegetable and/or animal raw material. The biologically active additive is prepared on base of natural raw material which is balanced at an optimum by essential components, and may show properties of adaptogens and detoxicants as well as common properties due to their interchangeable action. It broadens field of application of the additive, and gives a possibility to use it at various diseases. EFFECT: broadened assortment of food additives. 14 cl, 1 tbl, 3 ex
The present qualitative study is a part of the process evaluation of a complex intervention, the randomized controlled trial, "Prevention of human papillomavirus (HPV) in a school-based setting." We aimed to explore participating school nurses' perceptions and experiences of delivering the educational HPV intervention to adolescents aged 16. Focus group interviews were conducted with school nurses (n = 20) and analyzed with inductive qualitative content analysis. The overall theme Easily adapted into the existing role as a school nurse permeated the participants' views. The nurses were in favor of delivering an intervention that increased the HPV vaccination rates and improved beliefs and awareness about HPV prevention. It suits their work and health-promoting aspect of their role well and can easily be adapted into the current school health consultant curriculum. Having material in different languages to share with adolescents and their parents to promote equal health was deemed important.
BACKGROUND: Pulmonary alveolar microlithiasis (PAM) is a rare autosomal recessive genetic disorder with approximately 1000 known cases worldwide, in which calcium phosphate microliths deposit in the alveolar air spaces. As of writing this report, no definitive conventional therapy exists, and many PAM cases may progress to severe respiratory failure and potential death. Bilateral lung transplantation (BLx) seems to be the most optimal solution; however, this procedure is challenging along with limited reports regarding the outcome in PAM. We report a case of PAM successfully treated with BLx for the first time in Iran.
METHOD: We present the case of a 42-year-old female with a longstanding history of cough, not responding to conventional antitussive medication, who was diagnosed as a case of PAM following a hospitalization due to coughing, dyspnea on exertion, and hemoptysis. Despite treatment with corticosteroid and medical treatment, no improvement was achieved and she subsequently developed respiratory and right ventricular failure, with oxygen ventilation dependence. Eventually, she was scheduled for BLx. The operation was successful and during her 2-year follow-up, no recurrence or significant postoperative complications has been reported.
CONCLUSION: This case presentation and literature review confirm the effectiveness of BLx as a promising treatment for PAM-diagnosed patients, improving both life expectancy and quality of life.
In one example in accordance with the present disclosure, a fluid operation cell is described. The fluid operation cell includes a micro-electro-mechanical housing. The housing includes an inlet and an outlet through which fluid flows and electrodes disposed on an interior of the housing to couple to a controller. The fluid operation cell also includes a silicon-based substrate disposed inside, and electrically coupled to, the housing. The substrate includes an on-chip electrical fluid operation component formed thereon. The electrical fluid operation component uses an electrical signal to operate on bypassing fluid. The fluid operation cell includes a dedicated address to be individually activated by the controller.
Participants will self-administer FHIR-enhanced RealRisks with access to risk communication games, family history pedigree and modules on chemoprevention and genetics testing, if relevant to them based on their risk and family history. The investigators are interested in gaining short-term feedback on patient activation and other patient reported outcomes, which will be assessed before and within 2 weeks after using RealRisks.
Participants with tumors other than DSRCT and will be enrolled onto an assessment arm to determine eligibility. Immunohistochemistry to assess B7H3 expression will be performed on frozen or paraffin embedded tissue using omburtamab (frozen tissue) or a commercially available anti-B7H3 antibody (if paraffin embedded).
FIELD: cosmetic industry. SUBSTANCE: described is composition for photoprotection of skin and/or hair which comprises (i) filtering solubilized system composed of 4- methylbenzylidene-camphor (compound A), 4-(tert-butyl)-4- methoxydibenzoyl methane (compound B) and mixture thereof, and (ii) filtering solubilizing system composed of homomethyl salicylate (compound C), octyl salicylate (compound D) and mixture thereof, said system being in amount sufficient for solubilization of entire system therein. Said compounds are contained in cosmetically acceptable carrier, especially of oil-in-water type. Also described are composition solubilizer and method of protection of skin and/or hair from ultraviolet irradiation. EFFECT: maximum protection from entire spectrum of harmful ultraviolet irradiation. 19 cl, 3 ex
Pharmaceutical compositions comprising a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfate salt, an aryl sulfate salt or an alkyl aryl sulfonate salt of methylene blue or a derivative of methylene blue are described herein. The compositions are preferably administered orally and can be administered as tablets, soft or hard shell capsules (e.g. soft gelatin capsules), suspensions or solutions. The composition can also be formulated as a suppository or enema or rectal administration. The compositions further comprise a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients. Suitable excipients include diluents, binders, plasticizers, lubricants, disintegrants, colorants, stabilizers, surfactants, and combinations thereof. The fatty acid salts, alkyl sulate salts, aryl sulfate salts or alkyl aryl sulfonate salts can be co-mixed or co-melted with one or more fatty acids to make more hydrophobic compositions, which may result in less staining formulations. The compositions can be formulated for immediate release, controlled release such as extended release, delayed release, and pulsatile release, or combinations thereof. In one embodiment, the derivative of methylene blue is methylene dodecylsulfate.
INTRODUCTION: as cholera, due to toxigenic bacteria Vibrio cholera (serogroups O1 and O139), is a major public health threat in Africa, the aim of this work was to investigate potentially pathogenic Vibrionaceae bacteria firstly from human stool samples, and secondly from various environmental water points of Saint-Louis city in Senegal.
METHODS: a hospital-based study was conducted between 2013 and 2015. Stool samples were taken and cultured from daily incoming patients or hospitalized for acute diarrhea at Saint-Louis´ regional hospital. For environment, a monthly longitudinal sampling from January to October 2016 was carried out at 10 sites in the city. We used total DNA extracted from APW (alkaline peptone water) broth solutions and on suspect bacterial colonies to run PCR Multiplex targeting specific DNA fragments to detect Vibrio genus and specific species. In case of positivity, a simplex PCR was performed to test for cholera toxins Ctx, and V. parahaemolyticus TRH and TDH.
RESULTS: for 43 patients screened, bacterial culture was positive in 6% of cases but no strain of V. cholerae or other Vibrio sp. was isolated. PCR on 90 APW solutions were positive for Vibrio sp.(n = 43), V. cholera(n = 27), V. mimicus(n = 16), V. parahaemolyticus(8), V. alginolyticus(n = 4), and V. vulnificus(n = 2). Unlike for those on suspected colonies which were positive for a majority of V. parahaemolyticus (n = 40) and V. cholerae non-O1 / O139 (n = 35). Six strains of V. parahaemolyticus carried TRH gene, 3 of which expressed simultaneously virulence TRH and TDH genes. For physicochemical parameters, all temperatures varied similarly according to a unimodal seasonality, as well as salinity.
CONCLUSION: despite the presence of natural populations of Vibrionaceae, even toxigenic ones, was noted in water environment, along with favorable habitat conditions that could play a role in transmission of Vibriosis in the Saint Louis population, we did not isolate any of them from patients screened at the hospital.
The potential role of so called ‘cell adhesion recognition motifs’ (CARs) in cadherin adhesion has been emphasized. Due to the importance of cadherin binding in biological process, there remains a need to develop effective ways of manipulating cadherin adhesion. According to the present invention, there is provided a pair of cadherin molecules modified to enhance intermolecular adhesion (i.e. adhesion or binding between the pair of cadherin molecules) compared with corresponding unmodified cadherin molecules. Intermolecular adhesion between the cadherin molecules may be enhanced by reducing or eliminating intramolecular binding within each cadherin molecule. For example, intramolecular binding may be reduced or eliminated by diminishing or preventing intramolecular binding of an N-terminal binding strand of each cadherin molecule with a binding strand acceptor pocket of each cadherin molecule. Additionally or alternatively, the intramolecular binding may be reduced or eliminated by diminishing or preventing the formation of an intramolecular ionic bond between the NH2 terminus of each cadherin molecule with a contact acidic amino acid residue of each cadherin molecule.
BACKGROUND: Anastomotic leak is a serious complication after esophagectomy that has been associated with worse outcomes. However, identifying patients at increased risk for anastomotic leak remains challenging.
METHODS: Patients were included from the 2016 to 2021 National Surgical Quality Improvement Project database who underwent elective esophagectomy with gastric reconstruction for cancer. A multivariable logistic regression model was used to identify risk factors associated with anastomotic leak.
RESULTS: A total of 4,331 patients were included in the study, of whom 647 patients experienced anastomotic leak (14.9%). Multivariable logistic regression revealed higher odds of anastomotic leak with smoking (adjusted odds ratio 1.24, confidence interval 1.02-1.51, P = .031), modified frailty index-5 score of 1 (adjusted odds ratio 1.44, confidence interval 1.19-1.75, P = .002) or 2 (adjusted odds ratio 1.52, confidence interval 1.19-1.94, P = .000), and a McKeown esophagectomy (adjusted odds ratio 1.44, confidence interval 1.16-1.80, P = .001). Each 1,000/μL increase in white blood cell count was associated with a 7% increase in odds of anastomotic leak (adjusted odds ratio 1.07, confidence interval 1.03-1.10, P = .0005). Higher platelet counts were slightly protective, and each 10,000/ μL increase in platelet count was associated with 2% reduced odds of anastomotic leak (adjusted odds ratio 0.98, confidence interval 0.97-0.99, P = .001).
CONCLUSION: In this study, smoking status, frailty index, white blood cell count, McKeown esophagectomy, and platelet counts were all associated with the occurrence of anastomotic leak. These results can help to inform surgeons and patients of the true risk of developing anastomotic leak and potentially improve outcomes by providing evidence to improve preoperative characteristics, such as frailty.
The sample of the study consists of children who aged 0-17. It is planned to collect the research data in Akdeniz University Hospital Pediatric Hematology and Oncology Outpatient Clinic. Data Collection Tools are 'Personal Information Form for Children', 'Catheterization Description Form' and 'The Difficult Intravenous Access (DIVA) Score for children '. DIVA Score will be used pre-intervention to determine whether patients have a difficult vein. Children with DIVA score of 4 and above will be randomly assigned to the intervention and control groups. The attempt to place an IV catheter in children in the intervention group will be carried out by "pushing with saline" (SF) technique. In this way, it is predicted that the success of IV intervention in difficult vascular access will increase and the number of attempts will decrease significantly. Peripheral catheter placement in the control group will be performed with the traditional method routinely implemented by nurses.
Infectious diseases thrive in war-torn societies. The recent sharp increase in human conflict and war thus requires the development of disease mitigation tools that account for the specifics of war, such as the scarcity of important public health resources. We developed a compartmental, differential equation-based disease model that considers key social, war and disease mechanisms, such as gender homophily and the replacement of soldiers. This model enables the identification of optimal allocation strategies that, given limited resources required for treating infected individuals, minimize disease burden, assessed by total mortality and final epidemic size. A comprehensive model analysis reveals that the level of resource scarcity fundamentally affects the optimal allocation. Desynchronization of the epidemic peaks among several population subgroups emerges as a desirable principle since it reduces disease spread between different subgroups. Further, the level of preferential mixing among people of the same gender, gender homophily, proves to strongly affect disease dynamics and optimal treatment allocation strategies, highlighting the importance of accurately accounting for heterogeneous mixing patterns. Altogether, the findings help answer a timely question: how can infectious diseases be best controlled in societies at war? The developed model can be easily extended to specific diseases, countries and interventions.
All enrolled participants will receive the study intervention. Patients will receive up to 4 cycles of interventional agents prior to surgical resection. They will undergo imaging scans after the 2nd and 4th cycle (before surgery) of intervention agents. The short interval of scans (6 weeks) allows investigators to identify non responders. These patients may be encouraged to come off study and be treated based on the treating oncologist's choice. Since the investigational agents include 'standard of care' agents, a good argument can be made that these patients would not have benefitted from standard therapy only. Patients with at least stable disease after the 2nd treatment cycle will proceed with study interventions. However, patients with radiologic progression but who remain clinically stable may be allowed to continue treatment if the patient elects to, pending confirmation of progression and after a discussion between the investigator and sponsor-investigator.